Establishing an Innovation Alliance to Construct a Cardiovascular Industry Ecosystem

September 8th, the 23rd China International Fair For Investment & Trade grandly commenced in Xiamen, With the strong support of The Science and Technology Bureau of Xiamen Municipality, Xiamen Cardiovascular Hospital (abbreviated as XMCH) took the lead in officially launching the Xiamen Cardiovascular Health Industry-Technology Innovation Alliance. Additionally, a cardiovascular health industry signing ceremony took place, pooling multiple resources to bolster the growth of the cardiovascular health industry.

To further drive the growth of the cardiovascular health industry, the Xiamen Cardiovascular Health Industry-Technology Innovation Alliance (abbreviated as "Innovation Alliance") was officially initiated at the main venue of the fair.

XMCH spearheaded the alliance, partnering with research institutions from related fields and enterprises from all sectors of the industry chain. The first batch of member units consists of XMCH, Tan Kah Kee Innovation Laboratory, Xiang An Biomedicine Laboratory, Xiamen Biotime Biotechnology, MitrAssist Lifesciences Limited, Qilu Medical, Chenhui (Xiamen) Medical Device Co.,Ltd, Insync Biomed, J Medtech, VCBEAT Technology, and Xiamen Torch Biomedical Incubator Co.,Ltd., totaling 12 entities.

As a buzzword in the tech industry in recent years, the Innovation Alliance is an organizational mode where multiple entities collaboratively tackle challenges, prioritizing enterprises, market orientation, and deep integration of industry, academia, and research.

In China, 2 out of every 5 deaths result from cardiovascular diseases, making it the primary cause of mortality. The Innovation Alliance focuses on this domain with the shared goal of resolving core technical challenges in the cardiovascular health industry's growth. It aims to create a cardiovascular industry ecosystem in Xiamen through industry-academia-research collaboration, aiding urban economic and social progress.

"We will also utilize the 'BRICS Cardiovascular Health Innovation Center' platform to conduct further specialized technical training and talent cultivation. As we 'go global' technologically, we'll simultaneously promote the overseas sales of these innovative products," stated President Wang Yan.

Following the inauguration of the Innovation Alliance, an industry signing event took place. Medphoenix, Xiamen Torch Biomedical Incubator, and the BRICS Cardiovascular Health Innovation Center signed a letter of intent to jointly construct a comprehensive service platform for innovative medical device development targeting the BRICS countries.

The trio plans to rely on the BRICS PartNIR Innovation Center in Xiamen, aiming to develop a high-end comprehensive service platform for innovative cardiovascular medical devices tailored to BRICS and other international markets.

XMCH also entered into a strategic cooperation framework agreement with Shanghai MicroPort Medical (Group) Co., Ltd. In the past, MicroPort has resolved numerous "bottleneck challenges" in the cardiovascular sector, offering top-tier products to patients in China and globally. XMCH, being a regional medical center and research sub-center, boasts abundant clinical resources, research platforms, and technological prowess. The two parties intend to combine their strengths, focusing mainly on medical innovation concept verification, joint R&D of medical devices, the establishment of innovative medical device clinical training bases, and more, exploring an innovative system and model for industry-academia-research-medical collaborative growth.